Biocomputational Prediction of Anticancer Activity of Ayurvedic Plants Inhibiting Cyclin D1: Molecular Docking Study of the Major Active Compounds of Licorice Root Extract (Glycyrrhiza glabra) in Inhibiting Oral Squamous Cell Carcinoma Proliferation
Abstract
Background: Oral squamous cell carcinoma (OSCC) reported for > 90% of oral cancer cases, causing 377,713 new cases and 177,757 deaths in 2020. Treatments like surgery, chemotherapy, and radiotherapy affect patients’ lives. This study focuses on Licorice (Glycyrrhiza glabra) as an antineoplastic candidate targeting cyclin D1, crucial for cell proliferation in OSCC. It aims to predict licorice root extract (LRE) molecular mechanism against cyclin D1 and identify its most potent antineoplastic compound.
Method: The observational research employs a 2D biocomputational method. Ligand and enzyme require 2D isolation, human enzymes at 2–4 Å resolution, and >90% favorable regions. LRE and cyclin D1 are acquired from PubChem, RCSB PDB, PyMol, and Biovia. PyRx performs molecular docking, yielding quantitatively ∆Gbind values in kcal/mol, which indicate anticancer potency (lower values signify better efficacy).
Results: All common active compounds of LRE that have negative ∆Gbind values show that this compound can form bonds with the active site of cyclin D1 and inhibit its performance. The results of the molecular docking simulation also showed that 3 of the 9 LRE compounds had lower binding affinity values compared to the abemaciclib control, including glycyrrhetinic acid, liquiritin apioside, and 18β-glycyrrhetinic acid. These three compounds have binding affinity values of -5.5 kcal/mol, -5.3 kcal/mol, and -5.4 kcal/mol, respectively the most effective as an antineoplastic is glycyrrhetinic acid.
Conclusion: LRE had potential as antineoplastic against OSCC through cyclin D1 inhibition with the best being glycyrrhetinic acid.
Keywords
DOI: 10.33371/ijoc.v19i1.1180
Article Metrics
Abstract View: 695, 
PDF Download: 314
References
Panarese I, Aquino G, Ronchi A, et al. Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route. Expert Rev Anticancer Ther. 2019 Feb 1;19(2):105–19.
Kementerian Kesehatan RI. Riset Kesehatan Dasar Nasional 2018 [Internet]. RISKESDAS RI. 2019. Available from: https://repository.badankebijakan.kemkes.go.id/id/eprint/3514/1/Laporan%20Riskesdas%202018%20Nasional.pdf
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May 4;71(3):209–49.
Sarode G, Maniyar N, Sarode SC, et al. Epidemiologic aspects of oral cancer. Dis Mon. 2020 Dec;66(12):100988.
Abati S, Bramati C, Bondi S, et al. Oral Cancer and Precancer: A Narrative Review on the Relevance of Early Diagnosis. Int J Environ Res Public Health. 2020 Dec 2;17(24):1–14.
Kakkar V, Sarin V, Chatterjee A, et al. Expression of Cyclin-D1 and p53 as Prognostic Markers in Treatment of Oral Squamous Cell Carcinoma. Indian J Otolaryngol Head Neck Surg. 2022 Dec;74(Suppl 3):6136-45.
Ramos-García P, González-Moles MÁ, González-Ruiz L, et al. Clinicopathological significance of tumor cyclin D1 expression in oral cancer. Arch Oral Biol. 2019 Mar 1;99:177–82.
Arnold JT. Integrating ayurvedic medicine into cancer research programs part 2: Ayurvedic herbs and research opportunities. J Ayurveda Integr Med. 2023 Mar 1;14(2):100677.
Imanu SF, Leginis SN, Iqbal M, Surboyo MDC. Pomegranate extract mechanism in inhibiting the development of oral cancer: A review. Indonesian Journal of Dental Medicine. 2023 May 15;6(1):37–42.
Sharma D, Namdeo P, Singh P. Phytochemistry and Pharmacological Studies of Glycyrrhiza glabra: A Medicinal Plant Review. Int J Pharm Sci Rev Res. 2021 Mar 21;67(1):187–94.
Kwon YJ, Son DH, Chung TH, Lee YJ. A Review of the Pharmacological Efficacy and Safety of Licorice Root from Corroborative Clinical Trial Findings. J Med Food. 2020 Jan 1;23(1):12–20.
Ding Y, Brand E, Wang W, Zhao Z. Licorice: Resources, applications in ancient and modern times. J Ethnopharmacol. 2022 Nov 15;298:115594.
Pastorino G, Cornara L, Soares S, et al. Liquorice (Glycyrrhiza glabra): A phytochemical and pharmacological review. Phytother Res. 2018 Dec;32(12):2323-39.
Tuli HS, Garg VK, Mehta JK, et al. Licorice (Glycyrrhiza glabra L.)-Derived Phytochemicals Target Multiple Signaling Pathways to Confer Oncopreventive and Oncotherapeutic Effects. Onco Targets Ther. 2022 Nov 30;15:1419-48.
Wang Y, Xia W, Tao M, Fu X. Oncopreventive and Oncotherapeutic Potential of Licorice Chalcone Compounds: Molecular Insights. Mini Rev Med Chem. 2023;23(6):662-99.
Khozeimeh F, Dehghan P, Yaghoobi N, et al. Effect of nystatin and licorice on yeasts isolated from the oral lesions of patients with cancer under chemotherapy (in vitro study). Dent Res J (Isfahan). 2022;19:61.
Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci. 2019;20(18):4331.
Khoswanto C, Siswandono. Molecular Docking Analysis of Quercetin and Diclofenac as Cox-2 Potential Inhibitors. JIDMR. 2022;552–5.
Kusuma SMW, Utomo DH, Susanti R. Molecular Mechanism of Inhibition of Cell Proliferation: An In Silico Study of the Active Compounds in Curcuma longa as an Anticancer. J Trop Biodivers Biotechnol. 2022 Nov 14;7(3):74905.
Utomo DH, Kita M. Binding Mode of Actin–Aplyronine A–Tubulin Heterotrimeric Complex Revealed by Molecular Dynamics Simulation. Bull Chem Soc Jpn. 2023 Jan 13;96(2):120–6.
Pantsar T, Poso A. Binding Affinity via Docking: Fact and Fiction. Molecules. 2018 Jul 30;23(8):1899.
Saikia S, Bordoloi M. Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective. Curr Drug Targets. 2019 Oct 25;20(5):501–21.
Ji D, Xu M, Udenigwe CC, Agyei D. Physicochemical characterisation, molecular docking, and drug-likeness evaluation of hypotensive peptides encrypted in flaxseed proteome. Curr Res Food Sci. 2020 Nov 1;3:41–50.
Burley SK, Bhikadiya C, Bi C, et al. RCSB Protein Data bank: Tools for visualizing and understanding biological macromolecules in 3D. Protein Sci. 2022 Dec 1;31(12):e4482.
Irani S. New insights into oral cancer—Risk factors and prevention: A review of literature. Int J Prev Med. 2020;11(1):202.
Nandini DB, Rao RS, Hosmani J, et al. Novel therapies in the management of oral cancer: An update. Dis Mon. 2020 Dec;66(12):101036.
Mosaddad SA, Beigi K, Doroodizadeh T, et al. Therapeutic applications of herbal/synthetic/bio-drug in oral cancer: An update. Eur J Pharmacol. 2021;890:173657.
Wong TSC, Wiesenfeld D. Oral Cancer. Aust Dent J. 2018 Mar 1;63 Suppl 1:S91–9.
Moharil RB, Khandekar S, Dive A, Bodhade A. Cyclin D1 in oral premalignant lesions and oral squamous cell carcinoma: An immunohistochemical study. J Oral Maxillofac Pathol. 2020 May-Aug;24(2):397.
Abdelmalak M, Singh R, Anwer M, et al. The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance. Cancers (Basel). 2022 Nov 1 [cited 2024 Jan 6];14(21):5388.
Palumbo A, Lau G, Saraceni M. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer. Ann Pharmacother. 2019 Feb 1;53(2):178–85.
Listiyana A, Rachmawati YL, Susianti H, et al. Analysis of the Metabolite Compound of the Ethanol Extract of Chrysanthemum cinerariifolium Stem and Activity for inhibition of Oral Squamous Cell Carcinoma (OSCC) in silico study. Pharmacognosy Journal. 2023 Apr 30;15(2):393–8.
Velázquez-Libera JL, Durán-Verdugo F, Valdés-Jiménez A, et al. LigRMSD: A web server for automatic structure matching and RMSD calculations among identical and similar compounds in protein-ligand docking. Bioinformatics. 2020;36(9):2912–4.
Iqbal M, Kurniawan RV, Nurfani HDW, et al. Molecular docking analysis of major active compounds of pomegranate peel extract (Punica granatum L.) in inhibiting cyclooxygenase enzyme. WJARR. 2023 Dec 30;20(3):1824–42.
Berniyanti T, Iqbal M, Yaasir NI, et al. Anti-inflammatory ability of licorice (Glycyrrhiza glabra) root extract in cyclooxygenase-2 enzyme inhibition: In silico study. WJARR. 2024;21(1):1798-1804.
Khalesi S, Maleki L, Eskandari S, et al. Cyclin D1 and Ki-67 expression and its correlation with histopathological parameters and cervical lymph node metastasis in oral squamous cell carcinoma. Dent Res J (Isfahan). 2023 Oct 26;20:112.
Dar MS, Abbas R, Shah Z, et al. Immunohistochemical expression of E-Cadherin and Cyclin D1 in different grades of oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2023 Jul-Sep;27(3):476-80.
Hu YJ, Sun WW, Zhao TC, et al. Cyclin D1 overexpression enhances chemosensitivity to TPF chemotherapeutic agents via the caspase-3 pathway in oral cancer. Oncol Lett. 2020 Nov;20(5):154.
Al-Rawi NH, Kawas SA, Ani MA, et al. Prediction of Lymphovascular and Perineural Invasion of Oral Squamous Cell Carcinoma by Combined Expression of p63 and Cyclin D1. Eur J Dent. 2023 Oct;17(4):1170-8.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Email this article 
